Mehrab Rahmani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mehrab Rahmani has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Amirreza Naseri
Student Research Committee Tabriz University of Medical Sciences Tabriz Iran
2 shared publications - Mahnaz Talebi
Neurosciences Research Center (NSRC) Tabriz University of Medical Sciences Tabriz Iran
2 shared publications - Sarvin Sanaie
Research Center for Integrative Medicine in Aging, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Alireza Rahimi-Mamaghani
Clinical Research Development Unit of Tabriz Valiasr Hospital, University of Medical Sciences , Tabriz
1 shared publication Farinush Moradi
Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication- Hanie Karimi
Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences
1 shared publication
Latest Publications
- 17 December 2024
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 132, 110990
Association of serum levels of inflammation and oxidative stress markers with cognitive outcomes in multiple sclerosis; a systematic review
- 17 December 2024
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 132, 110990
Association of serum levels of inflammation and oxidative stress markers with cognitive outcomes in multiple sclerosis; a systematic review
- 29 December 2023
- Published by Springer Nature in Biological Trace Element Research
- Vol. 202 (10) , 4375-4386
Shining a Light on Selenium: a Meta-analysis of Supplementation in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the central nervous system. Selenium is a trace element with significant antioxidant activity. This study aimed to seek evidence concerning selenium supplementation in MS. A systematic search was performed on PubMed, Web of Science, Scopus, and Embase databases to identify the studies assessing the consumption rate, efficacy, and safety of selenium and selenium-containing supplementations in MS patients. The meta-analysis was performed using the Comprehensive Meta-Analysis and the risk of bias was evaluated using the Joanna Briggs Institute’s critical appraisal tools. A total of 9 studies were included, which consisted of six studies regarding the rate of selenium supplement consumption in MS patients, with a total sample size of 2381 patients. Based on the quantitative synthesis, 14.3% (95% CI, 12.8–16.0%; I2, 3.58%) of MS patients had current selenium supplements usage, and 11.3% (95% CI, 7.6–16.6%; I2, 81.40%) of patients had used selenium supplements previously. Although there is no evidence regarding supplementation with selenium alone, three RCT studies reported the safety of selenium-containing supplementation use in MS with improved inflammation and oxidative stress conditions. The findings of this study show that over 10% of patients with MS used selenium supplements, with no clinical significance supporting the benefits. There is a lack of evidence regarding the safety and efficacy of selenium supplements in MS patients. Due to the limited number of included studies and the lack of comprehensive and specific studies regarding selenium supplements in MS, the results must be interpreted with caution, and future clinical trials are required.
- 29 December 2023
- Published by Springer Nature in Biological Trace Element Research
- Vol. 202 (10) , 4375-4386
Shining a Light on Selenium: a Meta-analysis of Supplementation in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the central nervous system. Selenium is a trace element with significant antioxidant activity. This study aimed to seek evidence concerning selenium supplementation in MS. A systematic search was performed on PubMed, Web of Science, Scopus, and Embase databases to identify the studies assessing the consumption rate, efficacy, and safety of selenium and selenium-containing supplementations in MS patients. The meta-analysis was performed using the Comprehensive Meta-Analysis and the risk of bias was evaluated using the Joanna Briggs Institute’s critical appraisal tools. A total of 9 studies were included, which consisted of six studies regarding the rate of selenium supplement consumption in MS patients, with a total sample size of 2381 patients. Based on the quantitative synthesis, 14.3% (95% CI, 12.8–16.0%; I2, 3.58%) of MS patients had current selenium supplements usage, and 11.3% (95% CI, 7.6–16.6%; I2, 81.40%) of patients had used selenium supplements previously. Although there is no evidence regarding supplementation with selenium alone, three RCT studies reported the safety of selenium-containing supplementation use in MS with improved inflammation and oxidative stress conditions. The findings of this study show that over 10% of patients with MS used selenium supplements, with no clinical significance supporting the benefits. There is a lack of evidence regarding the safety and efficacy of selenium supplements in MS patients. Due to the limited number of included studies and the lack of comprehensive and specific studies regarding selenium supplements in MS, the results must be interpreted with caution, and future clinical trials are required.